Key result
Bovine rotavirus pentavalent vaccine proves safe and immunogenic in early-phase trials across age groups.
Why the study?
Is the bovine rotavirus pentavalent vaccine safe and immunogenic in adults, toddlers, and infants?
Is the bovine rotavirus pentavalent vaccine safe and immunogenic in adults, toddlers, and infants?
A newly developed bovine rotavirus pentavalent vaccine has demonstrated safety and immunogenicity in early-phase human trials, supporting its progression to Phase III efficacy studies.
Answers are grounded in this paper and cite their sources.
Does not yet alter practice; supports Phase III efficacy trials for this novel rotavirus candidate.
A bovine rotavirus pentavalent vaccine (BRV-PV) containing rotavirus human-bovine (UK) reassortant strains of serotype G1, G2, G3, G4 and G9 has been developed by the Serum Institute of India Ltd, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), USA. The vaccine underwent animal toxicity studies and Phase I and II studies in adults, toddlers and infants. It has been found safe and immunogenic and will undergo a large Phase III study to assess efficacy against severe rotavirus gastroenteritis.
No takes yet. Share an insight, caveat, or question.
Zade et al. (2014) conducted a review in severe rotavirus gastroenteritis. Bovine rotavirus pentavalent vaccine (BRV-PV) was evaluated on safety and immunogenicity. A bovine rotavirus pentavalent vaccine (BRV-PV) was found to be safe and immunogenic in Phase I and II studies in adults, toddlers, and infants.
Synapse has enriched 10 related papers. Consider them for comparative context: